Ciphergen is dedicated to the discovery, development and commercialization of novel, high-value molecular diagnostic tests to help physicians diagnose, select appropriate treatments and improve outcomes for patients. The company, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, cardiology, hematology and women’s health with an initial focus in ovarian cancer.
To discover and develop novel diagnostic biomarkers, Ciphergen is applying genomics and proteomic technologies to identify associations between genes, proteins and diseases. Our goal is to help physicians address unmet clinical needs by producing new genomic and proteomic-based tests that can be used to better diagnose, monitor and treat diseases to ultimately improve the lives of their patients.
A strategic alliance with Quest Diagnostics is the cornerstone of Ciphergen’s commercialization strategy in the U.S.